Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Exploring the lived experiences of individuals with cystic fibrosis after the implementation of elexacaftor/tezacaftor/ivacaftor for treatment.
Journal: Therapeutic advances in respiratory disease
Published: July 25, 2026
Utilization of Des-Gamma-Carboxy-Prothrombin in Estimating Vitamin K Status in People With Cystic Fibrosis: A Single Center Retrospective Review.
Journal: Pediatric pulmonology
Published: January 17, 2026
Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor-Tezacaftor-Ivacaftor-A Pilot Study.
Journal: International journal of molecular sciences
Published: November 20, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.
Journal: American journal of respiratory and critical care medicine
Published: June 02, 2025
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase-1 in Children With Cystic Fibrosis.
Journal: Pediatric pulmonology
Published: November 06, 2024
The continuing need for dornase alfa for extracellular airway DNA hydrolysis in the era of CFTR modulators.
Journal: Expert review of respiratory medicine
Published: August 23, 2024
Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis.
Journal: Frontiers in pediatrics
Published: June 30, 2024
Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators.
Journal: Current opinion in pulmonary medicine
Published: August 23, 2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.
Journal: American journal of respiratory and critical care medicine
Published: May 08, 2023
Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the "First in Cystic Fibrosis" Phase I Clinical Trial (CEASE-CF).
Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 19, 2022
A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: August 01, 2022
The use of tobramycin for Pseudomonas aeruginosa: a review.
Journal: Expert review of respiratory medicine
Published: March 23, 2022
Last Updated: 09/26/2026